Alto is developing a new generation of brain biomarker-based diagnostic tests and personalized treatments for use in mental health, based on a platform built from data aggregated at scale and cutting-edge artificial intelligence analysis tools.
Developing biomarkers for brain health
Alto was born out of work in the Stanford lab of CEO and Founder Amit Etkin, MD PhD, and a desire to translate these insights out of the lab and achieve impact on real-world clinical outcomes. Dr. Etkin is a Professor of Psychiatry at Stanford (bio), where he has led an extremely interdisciplinary lab aiming to understand the brain basis of psychiatric disease and develop novel treatments. In recognition of his groundbreaking vision, Dr. Etkin received the highly prestigious NIH Director’s Pioneer Award in 2017.
At Alto, our mission is to reimagine brain health by building a neurotechnology platform that will make treatment for mental illness more effective, faster, and personalized.
The scientific underpinnings of this work has, and continues to be, published in many of the most impactful journals in biology and medicine: